1. Andrews, P. A. and Howell, S. B., Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance.Cancer Cell, 2, 35–43 (1990).
2. Bitha, P., Carvajal, S. G., Citarella, R. V., Child, R. G., DelosSantos, E. F., Dunne, T. S., Durr, F. E., Hlavka, J. J., Lang, Jr, S. A., Lindsay, H. L., Morton, G. O., Thomas, J. P., Wallace, R. E., Lin, Y. L., Haltiwanger, R. C. and Pierpont, C. G.: Water-soluble-third generation antitumor platinum complexes, [2,2-bis (aminomethyl)-1,3-propanediol N,N′]-[1, 1-cyclobutanedicarboxylato(2−)-0,0′][tetrahydro-4H-4,4-dimethanamine-N,N′]platinum (II).J. Med. Chem., 32, 2015–2020 (1989).
3. Burchenal, J. H., Kalahar, K., Dew, K. and Lokys, L., Rationale for development of platinum analogs.Cancer Treat. Rep., 63, 1493–1498 (1979).
4. Carmichael, J., Degraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchel, J. B., Evaluation of tetrazolium based semiautomated colorimetric assay: Assessment of chemo-sensitivity testing.Cancer Res., 47, 936–938 (1987).
5. Harland, S. J., Smith, I. E., Smith, N. and Alison, D. L.,Platinum Coordination Complexes in Cancer Chemotherapy, Hacker, H. P., Douple, E. B. and Krakoff, I. H., Eds; Martius Nihoff Publishing, Boston MA, 1984, p352.